These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 32282587)
1. Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale. Godlewski BJ; Sobolik LI; King VJ; Harrod CS Obstet Gynecol; 2020 May; 135(5):1207-1213. PubMed ID: 32282587 [TBL] [Abstract][Full Text] [Related]
2. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth. Nelson DB; McIntire DD; Leveno KJ Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472 [TBL] [Abstract][Full Text] [Related]
3. FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth. Gandell DL; Randell MD; Gudeman JL Curr Med Res Opin; 2020 Aug; 36(8):1393-1401. PubMed ID: 32544354 [TBL] [Abstract][Full Text] [Related]
4. Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate). Cohen AW; Copel JA; Macones GA; Menard MK; Riley L; Saade GR Obstet Gynecol; 2011 Jun; 117(6):1408-1412. PubMed ID: 21471853 [TBL] [Abstract][Full Text] [Related]
5. Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database. Shinde M; Cosgrove A; Woods CM; Chang C; Nguyen CP; Moeny D; Ajao A; Kolonoski J; Tsai HT J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6291-6296. PubMed ID: 33926341 [TBL] [Abstract][Full Text] [Related]
6. Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research. Chang CY; Nguyen CP; Wesley B; Guo J; Johnson LL; Joffe HV N Engl J Med; 2020 Dec; 383(24):e131. PubMed ID: 33140923 [No Abstract] [Full Text] [Related]
7. Re-examining the Meis Trial for Evidence of False-Positive Results. Sibai B; Saade GR; Das AF Obstet Gynecol; 2020 Sep; 136(3):622-627. PubMed ID: 32769653 [TBL] [Abstract][Full Text] [Related]
8. FDA Revokes Approval for Preterm Birth Drug Makena. Harris E JAMA; 2023 May; 329(17):1444. PubMed ID: 37043247 [No Abstract] [Full Text] [Related]
9. PROLONG Clinical Study Protocol: Hydroxyprogesterone Caproate to Reduce Recurrent Preterm Birth. Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck T; Miller HS; Das AF; Birch R; Jozwiakowski MJ Am J Perinatol; 2018 Oct; 35(12):1228-1234. PubMed ID: 29702708 [TBL] [Abstract][Full Text] [Related]
10. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth. Hines M; Lyseng-Williamson KA; Deeks ED Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110 [TBL] [Abstract][Full Text] [Related]
11. Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth. Sibai B; Saade GR; Das AF; Gudeman J J Perinatol; 2021 Apr; 41(4):718-725. PubMed ID: 33057132 [TBL] [Abstract][Full Text] [Related]
12. Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate. ; Am J Obstet Gynecol; 2023 Jul; 229(1):B2-B6. PubMed ID: 37061078 [TBL] [Abstract][Full Text] [Related]
13. A national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval. Rebarber A; Fox N; Klauser CK; Saltzman D; Roman AS Clin Drug Investig; 2013 Aug; 33(8):571-7. PubMed ID: 23800978 [TBL] [Abstract][Full Text] [Related]
14. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial. Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479 [TBL] [Abstract][Full Text] [Related]
15. Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval. Greene MF; Klebanoff MA; Harrington D N Engl J Med; 2020 Dec; 383(24):e130. PubMed ID: 33140924 [No Abstract] [Full Text] [Related]
16. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials. Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278 [TBL] [Abstract][Full Text] [Related]
17. SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: pubs@smfm.org Am J Obstet Gynecol; 2020 Jul; 223(1):B16-B18. PubMed ID: 32277894 [TBL] [Abstract][Full Text] [Related]
18. Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act. Gee RE; Kuy S; Karas LO Obstet Gynecol; 2017 Dec; 130(6):1202-1206. PubMed ID: 29112651 [TBL] [Abstract][Full Text] [Related]